Drugs / WGc-043
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07349836 | Jan 2026 → Jan 2028 expected | Epstein-Barr virus-related tumor | Xinqiao Hospital of Chongqing | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07028047 | Jun 2025 → Jun 2027 expected | Epstein-Barr virus-related tumor | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WGc-043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07028047 ↗ |
| Modality | Messenger RNA (mRNA) | “a therapeutic tumor vaccine based on messenger RNA (mRNA) targeting tumor-specific antigens expressed in EBV-positive tumors” NCT07028047 ↗ |
| Route | Intramuscular | “WGc-043 Injection, intramuscular injection” NCT07028047 ↗ |